Health Condition 1: F332- Major depressive disorder, recurrent severe without psychotic features
Conditions
Interventions
Intervention1: Effect Of Ketamine On Patients With Moderate To Severe Depressive Disorder: Group-A subjects already on escitalopram will receive ketamine hydrochloride (0.5 mg/kg) intravenous infusion
Sponsors
Dayanand Medical College and Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Patient seeking treatment at the department of psychiatry, Dayanand Medical College & Hospital (DMCH), Ludhiana. Both males and females aged 18-65 years. Primary diagnosis of MDD without psychotic features based on DSM-5. Diagnosis of moderate-severe MDD defined by MADRS = 20. Patient who are taking escitalopram 10-20 mg for at least 4 weeks. Medically stable for study participation
Exclusion criteria
Exclusion criteria: Any other major psychiatric disorder in patients of Major Depressive Disorder. History of any known uncontrolled medical condition. Women who are pregnant or lactating. Patient who have not given consent for the study. Untreated hypertension
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome measures will be early response and early remission to treatment by improvement in severity of depression on MADRS. Response will be a more than 50% improvement on MADRS scale.Timepoint: reductions in MADRS score will be measured after 4 hrs post ketamine in every session | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measure will be decrease in suicidal ideation and adverse events in CADSSTimepoint: Patients will undergo prospective observation. Vitals (blood pressure, heart rate etc.,) will be monitored every 5 minutes throughout the time of infusion and every half hourly for 2 hours after infusion.he patients will be discharged after assessing them on Modified Aldrete Score. | — |
Countries
India
Contacts
Public ContactDR NAVKIRAN SOOCH MAHAJAN
DMCH
Outcome results
None listed